U.S. Cannabis Markets Are Overshooting Therapeutic THC:CBD Ratios | Research

The takeaway

Most medical cannabis products in the U.S. have THC:CBD ratios that would produce significant intoxication — and they look nearly identical to recreational products.

Read this if you use medical cannabis and wonder whether what you're buying is actually formulated for therapeutic benefit, or if you work in cannabis policy and care about the gap between medical claims and market reality.

What the researchers found

The ratio of THC to CBD in cannabis products matters enormously for therapeutic outcomes. CBD can modulate THC's effects — at certain ratios it can mitigate THC's psychoactive impact, while at other ratios it may actually enhance it. This study analyzed the actual THC:CBD ratios available in U.S. dispensaries and found that the market has dramatically overshot therapeutic targets.

The researchers categorized products into four clinically meaningful ratio groups based on published pharmacological research: ratios where CBD enhances THC effects (≥1:1 THC:CBD), where CBD has no significant effect (~1:2), where CBD may mitigate THC effects (1:2 to higher CBD), and CBD-dominant products. They then analyzed real dispensary product listings from nine U.S. states.

The result is striking: the vast majority of products in both medical and recreational programs cluster in the high-THC range where CBD either enhances or fails to counteract THC's intoxicating effects. Medical products were statistically indistinguishable from recreational ones in their THC:CBD profiles. This means patients seeking therapeutic cannabis are largely choosing from the same high-potency, intoxication-producing products available to recreational users.

States with combined medical-recreational programs showed slightly different ratio distributions than medical-only states, but the overall pattern of THC dominance held across all markets.

Why it matters

If the point of medical cannabis is therapeutic benefit with minimal intoxication, the market is failing. Patients looking for relief — whether for pain, anxiety, or sleep — are largely limited to products that will get them significantly high, because the THC:CBD ratios on dispensary shelves far exceed what research suggests is therapeutically optimal. This disconnect between science and market is a structural problem in legal cannabis.

The numbers in context

Data collected from nine U.S. states. Products were classified into four THC:CBD ratio categories. Medical cannabis product THC:CBD profiles were statistically similar to recreational products across markets. The majority of products in all categories fell into the highest-THC ratio group (≥1:1 THC:CBD, where CBD enhances rather than mitigates THC effects).

How the study worked

Observational analysis of online herbal dispensary product offerings from nine U.S. states. Products were categorized into four clinically significant THC:CBD ratio categories derived from pharmacological literature. Comparisons were made between medical and recreational programs, and between states with different market policies.

Who was studied

Data from online herbal dispensary product offerings across nine U.S. states.

What this study cannot tell us

Data comes from online product listings, which may not perfectly reflect what's actually purchased or recommended by dispensary staff. Products were categorized by labeled potency, which can differ from actual tested content. The four-category ratio framework is based on published pharmacology but simplified — individual responses to THC:CBD ratios vary. The study captures a snapshot; market composition changes as new products enter.

How to read the evidence

This is an observational market analysis with a solid pharmacological framework. The data clearly shows what's available, though it can't tell us what patients actually use or how they respond to these ratios.

When this study was published

Published in 2022. Dispensary product offerings change frequently, but the structural overrepresentation of high-THC products is likely still present.

The bigger picture

This connects directly to the potency escalation documented in RTHC-00071 (rising THC concentrations in U.S. cannabis products over time) and RTHC-00049 (European potency trends). While those studies track the raw increase in THC levels, this study shows the problem from the therapeutic angle: not only is THC getting stronger, but the ratio of CBD (which could counterbalance the THC) is completely out of whack for medical use. Together, these three studies form a potency cluster documenting a market that's optimizing for intoxication, not health.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Should regulators mandate minimum CBD content in medical cannabis products? Would labeling THC:CBD ratios prominently (like nutritional labels) help patients make better choices? Are dispensary staff recommending appropriate ratios for specific conditions, or defaulting to popular high-THC products?

Read the original research

Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot.

Frontiers in pharmacology, 13, 921493

Frontiers in Pharmacology is a reputable journal focusing on pharmacological research.

View on PubMed ↗Publisher’s paper ↗

Citation

Pennypacker, Sarah D; Cunnane, Katharine; Cash, Mary Catherine; Romero-Sandoval, E Alfonso. (2022). Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot.. Frontiers in pharmacology, 13, 921493. https://doi.org/10.3389/fphar.2022.921493